Protagonist Therapeutics (PTGX) Income from Continuing Operations (2015 - 2026)

Protagonist Therapeutics has reported Income from Continuing Operations for 12 years, with the latest figure at 3783000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 132.46% year-over-year to 3783000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 114739000.0 (down 304.31% YoY) and the FY2025 annual result came in at 130149000.0, down 147.3% from the prior year.
• Income from Continuing Operations improved to 3783000.0 in Q1 2026 per PTGX's latest filing, from 44384000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 207366000.0 in Q1 2024 and troughed at 66943000.0 in Q1 2022.
• A 5-year average of 5386941.18 and a median of 33725000.0 in 2023 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 178.95% in 2022, then soared 714.87% in 2024.
• Over 5 years, Income from Continuing Operations stood at 34940000.0 in 2022, then soared by 225.69% to 43915000.0 in 2023, then jumped by 199.7% to 131615000.0 in 2024, then sank by 133.72% to 44384000.0 in 2025, then surged by 108.52% to 3783000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 3783000.0, 44384000.0, and 39339000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.